A Review of Patient Preferences for Osteoporosis Drug Treatment
- PMID: 26286178
- PMCID: PMC4540772
- DOI: 10.1007/s11926-015-0533-0
A Review of Patient Preferences for Osteoporosis Drug Treatment
Abstract
Poor medication adherence is a major problem in chronic diseases such as osteoporosis that may partially be due to unaddressed patient values and preferences. Data on patient preferences could help clinicians to improve medication adherence and could also be useful in policy decisions and guideline development. This paper aims to identify literature reporting on the preferences of patients for osteoporosis drug medications. Several methods have been used to elicit patient preferences for medications and their characteristics including qualitative research, survey with ranking/rating exercises, discrete-choice experiments and clinical studies (crossover designs, open-label study). All these studies revealed that osteoporotic patients have preferences for medications and their attributes, in particular for less-frequent dosing regimens. Interestingly, variations in the preferences of patients were observed in most studies, suggesting the importance to take into account individual preference in decision-making to improve osteoporosis care.
Similar articles
-
Overcoming problems with adherence to osteoporosis medication.Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):677-89. doi: 10.1586/erp.10.76. Expert Rev Pharmacoecon Outcomes Res. 2010. PMID: 21155701 Review.
-
Patient preferences for osteoporosis in Spain: a discrete choice experiment.Osteoporos Int. 2011 Jun;22(6):1947-54. doi: 10.1007/s00198-010-1382-3. Epub 2010 Sep 14. Osteoporos Int. 2011. PMID: 20838770
-
Patients' preferences for osteoporosis drug treatment: a discrete-choice experiment.Arthritis Res Ther. 2014 Jan 31;16(1):R36. doi: 10.1186/ar4465. Arthritis Res Ther. 2014. PMID: 24479410 Free PMC article.
-
An evaluation of patients' preferences for osteoporosis medications and their attributes: the PREFER-International study.Clin Ther. 2007 Mar;29(3):488-503. doi: 10.1016/s0149-2918(07)80087-7. Clin Ther. 2007. PMID: 17577470
-
Medication Decision-making in Osteoporosis: Can We Explain Why Patients Do Not Take Their Osteoporosis Medications?Curr Osteoporos Rep. 2018 Dec;16(6):772-774. doi: 10.1007/s11914-018-0494-0. Curr Osteoporos Rep. 2018. PMID: 30374627 Review.
Cited by
-
Discrete Choice Experiments in Health Economics: Past, Present and Future.Pharmacoeconomics. 2019 Feb;37(2):201-226. doi: 10.1007/s40273-018-0734-2. Pharmacoeconomics. 2019. PMID: 30392040 Free PMC article.
-
Qianggu capsule for the treatment of primary osteoporosis: evidence from a Chinese patent medicine.BMC Complement Altern Med. 2017 Feb 13;17(1):108. doi: 10.1186/s12906-017-1617-3. BMC Complement Altern Med. 2017. PMID: 28193278 Free PMC article.
-
Patients as research partners in preference studies: learnings from IMI-PREFER.Res Involv Engagem. 2023 Apr 7;9(1):21. doi: 10.1186/s40900-023-00430-9. Res Involv Engagem. 2023. PMID: 37029449 Free PMC article.
-
Patient versus physician preferences for lipid-lowering drug therapy: A discrete choice experiment.Health Expect. 2024 Apr;27(2):e14043. doi: 10.1111/hex.14043. Health Expect. 2024. PMID: 38590082 Free PMC article.
-
Polymorphisms in key bone modulator cytokines genes influence bisphosphonates therapy in postmenopausal women.Inflammopharmacology. 2017 Apr;25(2):191-201. doi: 10.1007/s10787-017-0322-7. Epub 2017 Feb 21. Inflammopharmacology. 2017. PMID: 28220389
References
-
- Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA) Arch Osteoporos. 2013;8(1-2):136. doi: 10.1007/s11657-013-0136-1. - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical